# Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

> **NCT00093470** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 144 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Megakaryoblastic Leukemia
- Adult Acute Monocytic Leukemia
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With Maturation
- Adult Acute Myeloid Leukemia With Minimal Differentiation
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
- Adult Acute Myeloid Leukemia Without Maturation
- Adult Acute Myelomonocytic Leukemia
- Adult Erythroleukemia
- Adult Pure Erythroid Leukemia
- Alkylating Agent-Related Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Clinical Observation
- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT00093470
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-18
- **Primary completion:** 2015-02-20
- **Final completion:** —
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2024-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093470, "Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00093470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*